post solid result close thursday organ top-
line beat vs ep upsid vs revenu
ex-asc organ less sell day came
ahead street adjust reduct revenu
adopt mostli hit us gross margin
lower off-set sg
lower respect line higher interest expens off-set
lower tax rate led beat back strong
quarter manag rais organ revenu guidanc rang
organ growth year rais ep guidanc mid-
point includ dilut entellu
adjust one fewer sell day deliv solid
organ sale ep growth plu believ still conserv
top bottom line guidanc despit rais strong start year
reiter overweight rate rais ye pt
orthoped post anoth solid quarter due impact
walk greater detail adjust go-forward basi
model quarterli perform comparison street figur difficult stryker
overal ortho platform post sale organ ex-on less
sell day us knee busi continu grow ahead market
organ growth ou grew first quarter also saw total
knee done use mako robot hip overal organ
growth came organ us growth strong ou growth print
trauma extrem outperform strong print product
foot ankl portfolio us ou estim
impact less sell day ortho segment
medsurg sale grew ex-asc organ
medsurg print compos benefit novadaq acquisit
fx tailwind headwind adjust
compani continu see strong growth endoscopi organ ex-
novadaq instrument grew overal us
neg impact suppli issu relat puerto rico facil ramp-up
elsewher medic grew sustain declin
compani note strong perform intern busi driven
progress japan australia canada
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
anoth strong perform neurotech coupl benefit entellu off-set
continu weak spine look entir divis neurotech spine post
growth organ back one month entellu deal
close februari exclud impact neurotech post
anoth strong quarter cc growth organ growth roughli
driven doubl digit growth across hemorrhag ischem stroke
hand spine sale soft growth continu market
soft us impact double-digit price declin across core
portfolio exclud innov product like tritanium cage abl
fare better competitor benefit continu strength tritanium
portfolio even notic weak competitor organ
zimmer
quick explan account impact come print
point confus invest commun present stryker
adopt inorgan depress growth first
quarter new revenu recognit practic reclassifi certain cost
previous treat posit net revenu reduct sg instead
made decis implement standard go-forward basi decid
formal restat compar figur effect reach apples-to-appl
comparison must reduc sale non-gaap sg figur quarter
year mean pro-
forma sale figur compar growth pro-forma
figur compar
bridg organ growth quarter quarter report
headlin organ growth print despit land ahead consensu
expect drew concern inaccur perceiv lower growth
 us busi go move part total compani start
correct base adjust impact
explain report top-lin subtract
 growth subtract fx tailwind growth
add back impact one less sell day bring organ
figur repres organ y/i growth also
note impact higher us headwind
busi headwind help explain part soft
report sale vs street
 gross margin came street vs
repres nomin y/i improv adjust compani note
product effici fx gain off-set neg mix price
headwind oper spend better expect sg come slightli
lower expect vs vs y/i
sg improv reflect continu focu cost transform growth
initi ctg partial off-set acquisit cost plan invest ctg
erp project certain sell invest mako net oper margin
ahead street expect improv y/i improv despit face
headwind quarter recent acquisit go forward manag
peg underli oper improv year minimum
threshold line benefit favor interest incom tax came
realli underli help higher expect
benefit stock compens led cash ep ahead
street
anoth strong quarter belt manag rais top bottom-lin
guidanc top-lin manag rais guidanc organ growth
bottom-lin ep expect come
includ dilut entellu posit net
fx impact januari outlook manag
call ep ahead street
model updat model forecast ep
sale organ model ep
sale organ
invest thesi valuat risk
follow solid start year expect balanc
compani easili outperform street expect top
bottom line see multipl top-lin driver includ new product launch
multipl busi knee instrument neuro physio-control top
list easi comparison owe recal specif challeng
decre benefit physio-control lead top line grow
ahead street consensu well ahead med-tech peer
grow oper margin improv despit recent deal dilut
reflect increas volum improv product mix deal accret
didnt get recal stryker put
up-front spend new global erp system behind admittedli
expens stock view worth assum deliv
consensu outlook problem trade premium
year-end price target share valu stock project
earn outlook roughli line current multipl view
conserv admittedli one expens stock group
view worth assum deliv consensu
outlook problem trade premium peer
risk rate price
downsid risk rate price target includ slower growth key end
market increas competit price pressur downturn us capit
equip spend dilut
stryker corp summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
